{"id":"NCT00247273","sponsor":"Warner Chilcott","briefTitle":"A Study of Monthly Risedronate for Osteoporosis","officialTitle":"A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2008-03","completion":"2008-04","firstPosted":"2005-11-01","resultsPosted":"2011-06-21","lastUpdate":"2013-04-22"},"enrollment":1294,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"risedronate","otherNames":[]},{"type":"DRUG","name":"risedronate","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population","timeFrame":"Baseline to Month 12 - Endpoint","effectByArm":[{"arm":"5 mg Risedronate","deltaMin":3.425,"sd":null},{"arm":"150 mg Risedronate","deltaMin":3.54,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":49,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Estonia","Finland","France","Hungary","Lebanon","Norway","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":642},"commonTop":["Influenza","Back Pain","Arthralgia","Nasopharyngitis","Bronchitis"]}}